| human | Q5 |
| P496 | ORCID iD | 0000-0003-2329-2280 |
| P108 | employer | National Institute for Communicable Diseases | Q55641219 |
| University of the Witwatersrand | Q534643 | ||
| Scripps Research | Q793867 | ||
| P106 | occupation | researcher | Q1650915 |
| Q112566708 | A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q58115616 | Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions |
| Q27644515 | Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies |
| Q27026662 | HIV broadly neutralizing antibody targets |
| Q38666772 | HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights |
| Q34455457 | Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models |
| Q33912373 | Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual |
| Q36433894 | New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q112569831 | Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa |
| Q57751823 | Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7 |
| Q35672336 | South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication |
| Q36246403 | Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. |
| Q37409244 | Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site |
| Q35076717 | The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection |
| Q35943810 | UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C |
| Q60959639 | V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity |
| Q35034268 | Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes |
Search more.